Previous article

Dominance in the pharmaceutical sector: An overview of EU and national case law

While pharmaceutical companies are subject to sector-specific regulations, the industry is not exempt from competition law, as exemplified by the numerous investigations that are regularly conducted by competition authorities around the globe and the magnitude of the sanctions that have been levied on pharmaceutical companies in recent years. In Europe more specifically, competition law enforcement and market monitoring in the pharmaceutical sector has intensified since the European Commission (the “Commission”) finalized its sector inquiry in 2009, which at the time shed light on life-cycle management strategies of certain originator companies using a variety of instruments to prevent or delay generic entry on their market(s) for as long as possible. And the Commission has lived up to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Mélanie Thill-Tayara, Marion Provost, Dominance in the pharmaceutical sector: An overview of EU and national case law, 5 November 2020, e-Competitions Pharma & Dominance, Art. N° 88025

Visites 4295

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues